

# Evaluating the causal relationships between urate, blood pressure, and kidney function in the general population: a two-sample Mendelian Randomization study

Haotian Tang, MRes \*, Venexia M Walker, PhD \*, Tom R Gaunt, PhD\*

*April 24, 2024*

Corresponding Author:

Prof. Tom R Gaunt

Medical Research Council Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, United Kingdom.

Email: [Tom.Gaunt@bristol.ac.uk](mailto:Tom.Gaunt@bristol.ac.uk)

---

\*Medical Research Council Integrative Epidemiology Unit, Bristol Medical School, University of Bristol, Bristol,

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.  
United Kingdom

## Abstract

Associations between blood urate levels, blood pressure (BP), and kidney function have previously been reported in observational studies. However, causal inference between these three traits is challenging due to potentially bidirectional relationships. We applied bidirectional univariable Mendelian randomization (UVMR) to assess the causal relationships between urate levels, BP, and kidney function, proxied by estimated glomerular filtration rate (eGFR), by using genetic associations from both UK Biobank and CKDGen. We performed multivariable MR (MVMR) to assess the independent effects of urate and BP on eGFR. Effect estimates are presented as standard deviation (SD) change in outcome per SD increase in exposure [95% confidence interval]. UVMR analysis suggested a bidirectional causal effect between urate and eGFR (urate on  $\log(\text{eGFR})$ :  $\beta = -0.10$  [-0.22 to 0.02];  $\log(\text{eGFR})$  on urate:  $\beta = -0.11$  [-0.17 to -0.04]). There was strong evidence of bidirectional causal effects between urate and SBP (urate on SBP:  $\beta = 0.08$  [0.04 to 0.11]; SBP on urate:  $\beta = 0.13$  [0.08 to 0.18]). Similar bidirectional causal effects were identified between urate and DBP (urate on DBP:  $\beta = 0.09$  [0.05 to 0.14]; DBP on urate:  $\beta = 0.13$  [0.08 to 0.18]). However, there was weak evidence of a causal effect between BP and eGFR. MVMR results suggested the causal effect of urate on eGFR was independent of BP. Our results provide evidence for bidirectional causal effects between urate and both eGFR and BP, suggesting urate control as a potential intervention to reduce BP and decline in kidney function in the general population, but little evidence of a causal relationship between BP and eGFR.

## Introduction

Hyperuricemia, defined as an elevated urate level in the serum, is a common disorder affecting about 20.1% of people in the United States.<sup>1</sup> Hyperuricemia is associated with several different disorders, including gout, hypertension, and chronic kidney disease (CKD).<sup>2</sup> CKD is an irre-

versible and progressive disease, which can lead to end-stage renal disease requiring expensive treatments, such as dialysis or kidney transplantation. Elevated urate levels have been associated with a substantial positive risk of CKD in numerous epidemiological studies, and are a potential risk factor for the development and progression of renal disease in the general population.<sup>3-6</sup> However, urate, as the byproduct of purine metabolism, is primarily excreted via the kidneys. The natural relationship between urate and kidney function makes it difficult to identify whether the association between urate and CKD is causal, and if so, in which direction.

It has also been reported that higher urate levels are associated with an elevated risk of hypertension.<sup>7-9</sup> Primary hypertension patients commonly have hyperuricemia, which is more prevalent in patients with accelerated hypertension.<sup>10</sup> Hypertension and CKD are interlinked and represent huge global public health burdens, affecting around 31%<sup>11</sup> and 10%<sup>12</sup> of adults respectively. Renal function deteriorates with sustained hypertension, and blood pressure (BP) regulation deteriorates with progressive renal function loss.<sup>13</sup> Furthermore, the mouse uricase-knockout model has indicated higher urate levels affect the progression of hypertension and reduce kidney function.<sup>14</sup> Understanding the causal relationships between serum urate, BP, and kidney function might help reveal the underlying pathophysiological mechanisms and provide new evidence for clinical and lifestyle intervention.

Utilizing genetic variants as instrumental variables for exposure, Mendelian randomization (MR) can address some of the limitations of observational research including confounding and reverse causation, to evaluate causal inference. MR method relies upon the principle that alleles randomly segregate from parents to offspring, according to Mendel's Laws of Inheritance. Consequently, it is unlikely that offspring genotypes will be linked to population confounders, such as behavioral and environmental factors. Furthermore, issues with reverse causation are avoided because germline genetic variants are established at conception and temporally precede the risk factors

being researched.<sup>15,16</sup>

Our project aims were to assess the causal relationship between urate, BP, and kidney function in the general population by conducting bidirectional univariable MR (UVMR) and multivariable MR (MVMR) analyses. Kidney function was proxied by estimated glomerular filtration rate (eGFR; derived using serum creatinine). In addition, to examine how the effect of urate on hypertension differs during the life course, we assessed the effects of urate on early-, late-onset, and overall hypertension.

## **Methods and materials**

### **Study design and data source**

We conducted genome-wide association studies (GWAS) in UK Biobank (UKB) (UKB project 15825), to obtain the summary level data for urate, both systolic and diastolic BP (SBP and DBP), and early-onset, late-onset, and overall hypertension.<sup>17</sup> We also obtained the summary statistics of both urate<sup>18</sup> and eGFR,<sup>19,20</sup> from the GWAS of European-ancestry participants carried out by the Chronic Kidney Disease Genetics Consortium (the CKDGen Consortium). We differentiate between the urate datasets from CKDGen and UKB GWAS by labeling them as "Urate (CKDGen)"<sup>18</sup> and "Urate (UKB)", and distinguish between the two eGFR datasets from CKDGen as "eGFR (CKDGen2016)"<sup>20</sup> and "eGFR (CKDGen2019)".<sup>19</sup>

To validate the results of our GWAS for the continuous traits urate and BP, we examined their known causal effects on gout and stroke respectively as positive controls using UVMR. We then performed pairwise bidirectional UVMR analyses to evaluate the relationship between urate, BP, and eGFR in general European population samples. Next, we investigated the causal effects of urate on early-onset, late-onset, and overall hypertension by using UVMR. Finally, we used

MVMR to investigate the causal effects of urate and BP, independent of each other, on eGFR. All MR analyses conducted in this study are shown in Table 1 and the details of GWAS data used for MR analyses are in Table 2 (for positive control results, see Supplementary Materials). Our analysis code is available on GitHub ([https://github.com/Haotian2020/Urate\\_Project2024](https://github.com/Haotian2020/Urate_Project2024)).

## **GWAS in UKB**

UKB, a large population-based cohort, recruited over 500,000 individuals and collected extensive phenotypic and genotypic data.<sup>17</sup> We used the UKB GWAS pipeline, which has been developed by the Medical Research Council (MRC) Integrative Epidemiology Unit (IEU), to perform our GWAS.<sup>21</sup> We applied the linear mixed modeling approach, BOLT-LMM, to account for population stratification and relatedness. The covariates in the model included genotyping chip, sex, and age. We conducted urate, SBP, and DBP GWAS using the full UKB sample. For each continuous trait, data were cleaned by removing extreme values, defined as values more than four standard deviations (SDs) from the mean. The urate GWAS with the UKB full sample was used as a sensitivity analysis to avoid sample overlap as both urate<sup>18</sup> and eGFR<sup>19</sup> were from CKDGen, as sample overlap can cause bias in inverse-variance weighted (IVW) MR estimates.<sup>22</sup> Next, we conducted early-onset, late-onset, and overall hypertension GWAS. Hypertension was defined as participants with ICD10 codes I10 and I15 (primary and secondary hypertension respectively). The GWAS of early- and late-onset hypertension are described in section *Early- and late-onset hypertension*. Finally, we randomly divided the participants with urate data into two halves. For both subsets, we conducted urate, SBP, and DBP GWAS. This split-sample approach provided GWAS results in independent samples to address sample overlap concerns in the MVMR analyses.

## Instrument Selection

We selected instruments robustly associated with each phenotype at genome-wide significance ( $p < 5e-8$ ). Next, we used `ieugwasr` R package to perform linkage disequilibrium clumping with a window of 10,000kb and a maximum  $r^2$  threshold of 0.001 to select independent variants.<sup>23</sup> We calculated F-statistics, which are derived from the variance explained by instruments and the exposure sample size, to evaluate the strength of the genetic instruments for each UVMR analysis,<sup>24,25</sup> by using `TwoSampleMR` R package.<sup>26</sup> F-statistics are typically interpreted using an arbitrary threshold of 10 as an indicator for a strong instrument.

## Main analyses

### UVMR

To estimate the causal effects between urate, BP, and eGFR, we systematically conducted pairwise bidirectional two-sample MR analyses using the IVW method. Both urate and eGFR GWAS summary statistics were downloaded from the CKDGen consortium (<http://ckdgen.imbi.uni-freiburg.de/>).<sup>19</sup> GWAS summary statistics for SBP and DBP were obtained by conducting novel GWAS in UKB.<sup>17</sup> All GWAS details and UVMR can be found in Table 2 and Table 1. All analyses are presented on the SD scale (see Supplementary Materials).

### Early- and late-onset hypertension

We examined the causal effects of urate on early-onset, late-onset, and overall hypertension using UVMR. In the literature, the definition of early-onset hypertension varies from  $\leq 35$  to  $\leq 55$  years of age.<sup>27-32</sup> Given the UK National Institute for Health and Care Excellence (NICE) makes treatment recommendations based on whether patients are above or below 55 years old,<sup>33</sup> we defined the threshold for early-onset and late-onset hypertension as 55 years old. To reduce misclassifica-

tion, we set a 5-year window before and after the threshold of 55 years old. Therefore, early-onset hypertension was defined as a diagnosis at an age of  $\leq 50$  years; late-onset hypertension was defined as a diagnosis at an age of  $> 60$  years. To implement the threshold, the year and month of birth of participants, as well as the date that the ICD10 codes I10 and I15 were first reported, were extracted from UKB. We then randomly assigned a day of birth within the birth month to each participant and calculated the approximate age at which participants were diagnosed with hypertension.

## **MVMR**

To investigate whether the effects of urate on eGFR are independent of BP, we applied MVMR using summary level urate genetic associations<sup>18</sup> from CKDGen and BP genetic associations from UKB as exposure, with eGFR<sup>19</sup> from CKDGen as the outcome. Genetic instruments in MVMR still need to adhere to the instrumental variable assumptions and must be related to at least one exposure. MVMR allows for the inclusion of multiple exposures and separates the direct causal effects of each exposure in the model.<sup>34</sup> To determine whether the genetic instruments effectively predict each exposure while considering the presence of the other exposure within the MVMR model, we calculated the conditional F-statistic for each exposure.<sup>35</sup> A conditional F-statistic larger than the arbitrary threshold of 10 indicates that the genetic instruments for MVMR are likely to be strong.

## **Sensitivity analyses**

### **Sensitivity analyses for UVMR**

By assuming that all exposure SNPs are valid instrumental variables, the IVW method combines the effects of all these SNPs to obtain an overall weighted effect.<sup>36</sup> However, the validity of MR estimates depends on three assumptions (Figure S1). To evaluate the robustness of our findings,<sup>15</sup>

we performed different sensitivity analyses, including MR-Egger,<sup>37</sup> weighted median,<sup>38</sup> weighted mode, simple mode<sup>39</sup> and Steiger filtering.<sup>40</sup> When balanced pleiotropic effects are present, the MR-Egger method exhibits resilience by permitting the intercept in the regression of the SNP-outcome association against the SNP-exposure association to be non-zero. The intercept term in the MR-Egger result can be used as an assessment of directional pleiotropy, with the intercept term being interpreted as a measure of the directional pleiotropy present (pleiotropy tests).<sup>37</sup> MR-Egger makes the ‘NO Measurement Error’ (NOME) assumption.<sup>41,42</sup> We calculated the  $I_{GX}^2$  statistics to assess any violation of the NOME assumption. When taken as an estimate of the attenuation bias, an  $I_{GX}^2$  statistic higher than 90% corresponds to less than 10% relative bias towards the null.<sup>41</sup> The weighted median method can provide reliable results even when a maximum of 50% of the instruments are not valid.<sup>38</sup> The mode method assumes that instruments from the largest subset are valid and identify the same true causal effect.<sup>39</sup> Finally, we applied Steiger filtering to ensure that each genetic instrument had a stronger association with the exposure than with the outcome, which minimized the risk of reverse causation in bidirectional MR.<sup>40</sup>

We applied Cochran’s Q-test to assess heterogeneity in each MR analysis by examining the variability in the causal effects of each genetic instrument. When Q significantly exceeds its degrees of freedom (which is calculated as the number of SNPs minus 1), it indicates the presence of heterogeneity.<sup>43,44</sup>

To address the sample overlap issue that both the urate and eGFR GWAS from CKDGen used many of the same individuals, we performed a urate GWAS using UKB data and repeated our UVMR analyses to assess the causal relationship between urate and eGFR in non-overlapping samples.

Additionally, to assess the reliability of the instruments for urate, SBP, and DBP, we performed three positive control MR analyses. These were urate on gout, SBP on stroke, and DBP on stroke



(see Supplementary Materials).

### **Sensitivity analyses for eGFR GWAS**

Multiple eGFR GWAS datasets are available from CKDGen.<sup>19,20,45</sup> To confirm the causal relationship between BP and eGFR as well as address the sample overlap problem in MR analyses, we used eGFR GWAS<sup>20</sup> (OpenGWAS<sup>46</sup> ID: ieu-a-1105) for sensitivity analyses between eGFR and BP. Additionally, we used BP instruments to compare their SNP effect on  $\log(\text{eGFR})$  from two eGFR GWAS<sup>19,20</sup> (see Supplementary Method).

### **Sensitivity analyses for MVMR**

Due to the sample overlap problem in which urate<sup>18</sup> and eGFR<sup>19</sup> GWAS were both from CKDGen, we used urate from UKB as a sensitivity analysis. As mentioned before, we applied the split-sample method for urate, SBP, and DBP to ensure non-overlapping samples in each MVMR analysis. We then conducted MVMR analyses using each split sample, followed by a meta-analysis using a fixed-effect model to obtain a single estimate. The conditional F-statistic of each exposure was calculated as the mean conditional F-statistic of the meta-analyzed MR analyses.

## **Results**

For all results, effect estimates (beta) are presented as standard deviation (SD) change in continuous outcome per SD unit increase in exposure [95% confidence interval] (OR (odds ratio) for binary outcome).

## UVMR

All the UVMR results, with and without Steiger Filtering, are provided in Supplementary Tables (ST) 5, 6, and 7.

### **Association of genetically predicted urate levels with BP and eGFR**

As shown in Figure 1A, genetically predicted higher urate increased SBP and DBP by 0.08 [95% CI: 0.04 to 0.11;  $p=6.5e-5$ ] and 0.09 [95% CI: 0.05 to 0.14;  $p=3.5e-5$ ] SD respectively. The evidence of the causal estimate of urate from CKDGen on eGFR was weak [ $\beta=-0.10$ ; 95% CI: -0.22 to 0.02;  $p=0.12$ ] while the evidence of the causal estimate of urate from UKB on eGFR was stronger [ $\beta=-0.17$ ; 95% CI: -0.24 to -0.09;  $p=1.6e-5$ ], with an effect size consistent with the less precise CKDGen estimate.

### **Association of genetically predicted BP with urate and eGFR**

As shown in Figure 1B and 1 C, genetically predicted higher BP increased urate levels [SBP:  $\beta=0.13$ ; 95% CI: 0.08 to 0.18;  $p=2.3e-8$ ; DBP:  $\beta=0.13$ ; 95% CI: 0.08 to 0.18;  $p=6.5e-8$ ]. However, there is little evidence for the effects of genetically elevated BP on  $\log(eGFR)$  [SBP:  $\beta=-0.02$ ; 95% CI: -0.08 to 0.04;  $p=0.50$ ; DBP:  $\beta=-0.06$ ; 95% CI: -0.13 to 0.004;  $p=0.64$ ].

### **Association of genetically predicted eGFR levels with urate and BP**

Genetically predicted higher  $\log(eGFR)$  decreased urate levels from both CKDGen [ $\beta=-0.10$ ; 95% CI: -0.17 to -0.04;  $p=1.0e-3$ ] (Figure 1D) and UKB [ $\beta=-0.11$ ; 95% CI: -0.18 to -0.04;  $p=1.1e-3$ ] (ST 5). There was little evidence supporting a causal effect of genetically predicted eGFR on SBP [ $\beta=0.01$ ; 95% CI: -0.02 to 0.05;  $p=0.51$ ] or DBP [ $\beta=-0.02$ ; 95% CI: -0.05 to 0.02;  $p=0.37$ ].

## **Association of genetically predicted urate levels with early-onset, late-onset, and overall hypertension**

As demonstrated in Figure 2, genetically increased urate levels led to a higher risk of early-onset, late-onset, and overall hypertension. The IVW analysis revealed that for each SD increase in genetically predicted urate, the risk of early-onset hypertension increased [OR=1.28; 95% CI: 1.07 to 1.53;  $p=6.1e-3$ ], as did the risk of late-onset hypertension [OR=1.17; 95% CI: 1.10 to 1.26;  $p=5.4e-6$ ] and overall hypertension [OR=1.22; 95% CI: 1.12 to 1.32;  $p=2.5e-6$ ] (ST 7).

### **Sensitivity analyses of UVMR**

The genetic instruments used in all UVMR analyses, with their F-statistics and  $I_{GX}^2$  statistics, are shown in ST 2 and 4 respectively. All instruments had F-statistics larger than 10 indicating that they are likely strong instruments. All  $I_{GX}^2$  were larger than 98.64% indicating that the NOME assumption is unlikely to have been violated. However, in all UVMR except urate on gout, Cochran's Q was much higher than its degrees of freedom, indicating the presence of heterogeneity (see ST 3).

The results of pleiotropy tests of UVMR without Steiger filtering are shown in ST 4. There was directional pleiotropy in the analysis of urate on early-onset hypertension [intercept=0.016;  $p=2.2e-3$ ]. There was negligible directional pleiotropy in the analysis of urate from CKDGen on SBP [intercept=0.003;  $p=1.4e-3$ ] and DBP [intercept=0.005;  $p=4.1e-5$ ], urate from UKB on eGFR [intercept=-0.004;  $p=6.7e-3$ ], SBP on urate from CKDGen [intercept=0.003;  $p=4.0e-3$ ], urate on late-onset hypertension [intercept=0.005;  $p=1.0e-2$ ] and overall hypertension [intercept=0.008;  $p=1.0e-3$ ]. There was limited evidence of directional pleiotropy for the rest of the main analyses. The weighted median results indicated a similar signal from the pleiotropy tests with evidence of pleiotropy affecting the causal estimate of urate on early-onset hypertension [OR=1.13; 95% CI:

0.91 to 1.40;  $p=0.26$ ]. Other weighted median results showed consistent evidence with the IVW results, consistent with the negligible pleiotropy effect found using MR-Egger, with the exception of urate (CKDGen) on eGFR [weighted median:  $\beta=-0.06$ ; 95% CI: -0.10 to -0.02;  $p=5e-3$ ]. All positive control MR results are shown in Supplementary Materials and Figure S2.

Although Steiger filtering removed between 0 and 52 SNPs in the bidirectional UVMR analyses, the causal estimates from IVW remained consistent with the results of the main analyses.

### **Sensitivity analyses for eGFR GWAS**

The results of bidirectional UVMR between eGFR (CKDGen2016) and BP were consistent with the main analyses involving eGFR (CKDGen2019) and BP, indicating weak evidence of causal effects between eGFR (CKDGen2016) and BP (see Supplementary Materials).

### **MVMR: Independent association of genetically predicted urate and BP levels with eGFR**

The conditional F-statistics of instruments of each exposure were greater than 10, indicating the genetic instruments in MVMR were strong (ST 8). The MVMR provided evidence that increased urate has a causal effect on decreased eGFR, independent of SBP (Figure 3A), and DBP (Figure 3B). Changes in SD  $\log(eGFR)$  per SD increase in genetically predicted urate were -0.10 [adjusted with SBP; 95% CI: -0.18 to -0.02;  $p = 1.2e-2$ ] and -0.12 [adjusted with DBP; 95% CI: -0.20 to -0.04;  $p=4.1e-3$ ]. There was little evidence of a causal effect of genetically predicted higher SBP or DBP on eGFR, independent of urate [SBP:  $\beta = -0.03$ ; 95% CI: -0.13 to 0.07;  $p=0.58$ ; DBP:  $\beta=-0.09$ ; 95% CI: -0.19 to 0.01;  $p=6.8e-2$ ]. All these independent causal estimates were consistent with the MVMR results using the split-sample method (Figure S3).

## Discussion

We examined the causal relationships between urate, BP, and eGFR by conducting pairwise UVMR and MVMR of urate and BP on eGFR. The UVMR results indicated strong evidence of bidirectional causal effects between urate and BP (both SBP and DBP) and between urate and eGFR. There was also evidence of causal effects of urate on early-onset, late-onset, and overall hypertension, but we could not distinguish whether urate has a larger effect on early-onset hypertension. However, we find inconclusive evidence of causal effects between BP and eGFR. MVMR results indicated that the causal effects of urate on eGFR were independent of BP.

Previously, a bidirectional MR found strong evidence of the causal effect of higher eGFR on lower SBP and DBP, but not vice versa.<sup>47</sup> This study used eGFR and blood urea nitrogen (BUN) summary statistics to select genetic instruments for eGFR. Given that higher eGFR results in lower BUN, they assumed eGFR instruments relevant to kidney function, for example, with a positive association with eGFR, should correspondingly have a negative association with BUN. They concluded that better eGFR is causal to lower BP. However, our study does not support the evidence of a causal effect of eGFR on BP. This could be due to the differences in the instrument selection approach or because the BP GWAS used in the previous study was additionally adjusted for body mass index,<sup>48</sup> while we conducted our BP GWAS only adjusting for genotyping chip, sex, and age in UKB. Numerous epidemiological studies have reported that elevated blood pressure is a risk factor for both the onset and progression of CKD<sup>49–53</sup> and CKD can also arise as a complication of untreated high blood pressure. Several pathophysiologic mechanisms between BP and kidney function have also been studied 1) from high blood pressure to reduced eGFR, such as endothelial injury;<sup>54</sup> 2) from reduced eGFR to high blood pressure, such as increased activity of the renin-angiotensin-aldosterone system and sodium dysregulation.<sup>13,55</sup> Conducting Two-sample MR requires the underlying assumption of a linear relationship between exposure and outcome.

Renal autoregulatory mechanisms can protect the kidney from the influence of systemic BP and maintain the glomerular hydrostatic pressures.<sup>56,57</sup> As the majority of UKB participants were relatively healthy, renal autoregulation may attenuate the effects of BP on eGFR observed in MR. Due to concerns about the reliability of non-linear MR,<sup>58</sup> we did not apply non-linear MR to the analyses between BP and eGFR. The weak evidence of causal effects of eGFR on BP may result from biased estimates due to eGFR overestimation compared to measured mGFR using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.<sup>59</sup>

A previous MR study, using 26 SNPs identified from a cohort of 110,347 individuals of European ancestry by the Global Urate Genetics Consortium,<sup>60</sup> found limited evidence of a causal relationship between urate and either eGFR or the risk of developing CKD.<sup>61</sup> Another MR study using a genetic urate score indicated hyperuricemia could predict the risk of gout but did not demonstrate predictive power for the development of hypertension or CKD.<sup>62</sup> However, these results could reflect the limited number of genetic instruments and outcome sample size used in these studies. Our MR results with larger sample sizes of both urate and other traits showed consistent results with one previous MR study,<sup>63</sup> that found serum urate had a causal effect on increased SBP. Additionally, we identified a bidirectional causal relationship, indicating that elevated BP also leads to increased urate levels.

Assessing the causal role of urate on kidney function in epidemiological studies is challenging due to the inherent relationship between urate and the kidneys. Urate is primarily excreted by the kidneys, and if kidney function is compromised, there is compensatory but insufficient elimination by the gut.<sup>64</sup> Rat experiments have revealed that elevated urate levels impact the proliferation and oxidative stress in vascular smooth muscle cells through the activation of the renin-angiotensin system,<sup>65</sup> and cause endothelial dysfunction,<sup>66</sup> which contributes to the development of glomerular and systemic hypertension.<sup>67-69</sup> However, in cases of renal disease, the importance of these

mechanisms from experimental studies might be diminished, as systemic hypertension often occurs due to sodium and water retention. This leads to the failure to predict CKD progression using urate.<sup>70,71</sup> Our study provides further insight by using UVMR with and without Steiger filtering and MVMR, which allows us to estimate the effect of urate, independent of blood pressure, on eGFR and the effect of blood pressure, independent of urate, on eGFR.

Rat experiments indicate that the relationship of urate with hypertension may change based on renal microvascular damage and interstitial inflammation. Early urate-lowering treatments can reduce BP, but hypertension becomes kidney-dependent and irreversible with the progressing renal arteriolopathy and tubulointerstitial inflammation.<sup>14,72,73</sup> Moreover, the correlation between urate levels and hypertension diminishes with increasing age and duration of hypertension, suggesting a potential significance of urate in younger individuals with early-onset hypertension.<sup>74,75</sup> Thus, we conducted a novel MR analysis of urate on early-onset, late-onset, and overall hypertension. While we observed a causal effect of urate on all hypertension types, including some evidence of a directional pleiotropy effect for early-onset hypertension, the wide confidence interval of the effect of urate on early-onset hypertension precludes distinguishing its effect magnitude from that on late-onset hypertension. This is likely due to the sample size as there were only 6,934 cases in the early-onset hypertension GWAS.

Our study had several strengths. Firstly, we harnessed the power of large sample sizes from UKB and CKDGen, which increased the instrument strength in both UVMR and MVMR and decreased the probability of violation of the MR relevance assumption. Secondly, we proactively addressed sample overlap issues in UVMR and MVMR analyses caused by the fact that both urate and eGFR GWAS were taken from CKDGen. We addressed this by using the GWAS conducted with the full UKB sample and the split-sample method in the UVMR and MVMR sensitivity analyses respectively. Both indicated limited evidence of bias caused by the sample overlap. Thirdly, we con-

ducted all bidirectional MR analyses with Steiger filtering to mitigate potential reverse causality concerns between urate, BP, and eGFR. Lastly, we validated the robustness of our findings through a comprehensive set of MR sensitivity analyses, including approaches robust to pleiotropic effects, such as the weighted median and weighted mode methods in UVMR.

Consideration of limitations is essential when interpreting our results. Although sensitivity analyses have shown that most of the pleiotropy effects in our MR analyses are likely to be balanced, the heterogeneity tests indicate a potential violation of the horizontal pleiotropy assumption. Furthermore, despite a relatively large sample from UKB, the cases of early-onset hypertension were limited because the median age at recruitment in UKB is 58 (minimum: 37; maximum: 73). Thus, the power of our MR analysis of urate on early-onset hypertension was limited, resulting in a wide confidence interval. Finally, we only used European-summary-level data in our analyses, which may limit the generalizability of our findings to other ancestries.

In conclusion, we found bidirectional causal effects between urate and both BP and eGFR in the general population. The effects of urate on eGFR were independent of BP. Our findings suggest for the general population, controlling serum urate levels might help to reduce BP and maintain kidney function. Implementing lifestyle modifications or treatment aimed at reducing urate serves as a pragmatic and effective strategy for improving cardiovascular and renal health on a population scale.

## References

1. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007–2016. *Arthritis & rheumatology*. 2019;71(6):991–999.



2. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. *New England journal of medicine*. 2008;359(17):1811–1821.
3. Dawson J, Jeemon P, Hetherington L, *et al*. Serum uric acid level, longitudinal blood pressure, renal function, and long-term mortality in treated hypertensive patients. *Hypertension*. 2013;62(1):105–111.
4. Kumagai T, Ota T, Tamura Y, Chang WX, Shibata S, Uchida S. Time to target uric acid to retard CKD progression. *Clinical and experimental nephrology*. 2017;21:182–192.
5. Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: a systematic review and meta-analysis based on observational cohort studies. *BMC nephrology*. 2014;15:1–12.
6. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. *Journal of the American Society of Nephrology: JASN*. 2008;19(6):1204.
7. Gaffo AL, Jacobs DR, Sijtsma F, Lewis CE, Mikuls TR, Saag KG. Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort. *Annals of the rheumatic diseases*. 2013;72(8):1321–1327.
8. Mancia G, Grassi G, Borghi C. Hyperuricemia, urate deposition and the association with hypertension. *Current medical research and opinion*. 2015;31(sup2):15–19.
9. Sanchez-Lozada LG, Rodriguez-Iturbe B, Kelley EE, *et al*. Uric acid and hypertension: an update with recommendations. *American journal of hypertension*. 2020;33(7):583–594.
10. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. *hypertension*.

2003;42(3):247–252.

11. Mills KT, Bundy JD, Kelly TN, *et al.* Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. *Circulation*. 2016;134(6):441–450.
12. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. *The lancet*. 2021;398(10302):786–802.
13. Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: core curriculum 2019. *American Journal of Kidney Diseases*. 2019;74(1):120–131.
14. Watanabe S, Kang DH, Feng L, *et al.* Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. *Hypertension*. 2002;40(3):355–360.
15. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. *Statistics in medicine*. 2008;27(8):1133–1163.
16. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Human molecular genetics*. 2014;23(R1):R89–R98.
17. Sudlow C, Gallacher J, Allen N, *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS medicine*. 2015;12(3):e1001779.
18. Tin A, Marten J, Halperin Kuhns VL, *et al.* Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels. *Nature genetics*. 2019;51(10):1459–1474.

19. Wuttke M, Li Y, Li M, *et al.* A catalog of genetic loci associated with kidney function from analyses of a million individuals. *Nature genetics*. 2019;51(6):957–972.
20. Pattaro C, Teumer A, Gorski M, *et al.* Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. *Nature Communications*. 2016;7(1).
21. Mitchell R, Hemani G, Dudding T, Corbin L, Harrison S, Paternoster L. UK Biobank Genetic Data: MRC-IEU Quality Control, version 2. *University of Bristol*. 2019.
22. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample Mendelian randomization. *Genetic epidemiology*. 2016;40(7):597–608.
23. Hemani G, Elsworth B, Palmer T, Rasteiro R. *ieugwasr: Interface to the 'OpenGWAS' Database API 2024*. R package version 0.2.2-9000, <https://mrcieu.github.io/ieugwasr/>.
24. Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in Mendelian randomization studies. *International journal of epidemiology*. 2011;40(3):755–764.
25. Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *bmj*. 2018;362.
26. Hemani G, Zheng J, Elsworth B, *et al.* The MR-Base platform supports systematic causal inference across the human phenome. *elife*. 2018;7:e34408.
27. Wang NY, Young JH, Meoni LA, Ford DE, Erlinger TP, Klag MJ. Blood pressure change and risk of hypertension associated with parental hypertension: the Johns Hopkins Precursors Study. *Archives of internal medicine*. 2008;168(6):643–648.
28. Niiranen TJ, McCabe EL, Larson MG, *et al.* Heritability and risks associated with early onset

- hypertension: multigenerational, prospective analysis in the Framingham Heart Study. *Bmj*. 2017;357.
29. Niiranen TJ, Larson MG, McCabe EL, Xanthakis V, Vasan RS, Cheng S. Prognosis of prehypertension without progression to hypertension. *Circulation*. 2017;136(13):1262–1264.
  30. Niiranen TJ, McCabe EL, Larson MG, *et al*. Risk for hypertension crosses generations in the community: a multi-generational cohort study. *European heart journal*. 2017;38(29):2300–2308.
  31. Suvila K, McCabe EL, Lehtonen A, *et al*. Early onset hypertension is associated with hypertensive end-organ damage already by midlife. *Hypertension*. 2019;74(2):305–312.
  32. Vaura F, Kauko A, Suvila K, *et al*. Polygenic risk scores predict hypertension onset and cardiovascular risk. *Hypertension*. 2021;77(4):1119–1127.
  33. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. Management of hypertension: summary of NICE guidance. *Bmj*. 2011;343.
  34. Burgess S, Thompson SG. Multivariable Mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. *American journal of epidemiology*. 2015;181(4):251–260.
  35. Sanderson E, Spiller W, Bowden J. Testing and correcting for weak and pleiotropic instruments in two-sample multivariable Mendelian randomization. *Statistics in medicine*. 2021;40(25):5434–5452.
  36. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. *Genetic epidemiology*. 2013;37(7):658–665.

37. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. *International journal of epidemiology*. 2015;44(2):512–525.
38. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. *Genetic epidemiology*. 2016;40(4):304–314.
39. Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data Mendelian randomization via the zero modal pleiotropy assumption. *International journal of epidemiology*. 2017;46(6):1985–1998.
40. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLoS genetics*. 2017;13(11):e1007081.
41. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan NA, Thompson JR. Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I<sup>2</sup> statistic. *International journal of epidemiology*. 2016;45(6):1961–1974.
42. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. *European journal of epidemiology*. 2017;32:377–389.
43. Greco M FD, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian randomisation studies with summary data and a continuous outcome. *Statistics in medicine*. 2015;34(21):2926–2940.
44. Bowden J, Del Greco M F, Minelli C, *et al*. Improving the accuracy of two-sample summary-data Mendelian randomization: moving beyond the NOME assumption. *International journal*

*of epidemiology*. 2019;48(3):728–742.

45. Stanzick KJ, Li Y, Schlosser P, *et al*. Discovery and prioritization of variants and genes for kidney function in gt;1.2 million individuals. *Nature Communications*. 2021;12(1).
46. Elsworth B, Lyon M, Alexander T, *et al*. The MRC IEU OpenGWAS data infrastructure. 2020.
47. Yu Z, Coresh J, Qi G, *et al*. A bidirectional Mendelian randomization study supports causal effects of kidney function on blood pressure. *Kidney international*. 2020;98(3):708–716.
48. Evangelou E, Warren HR, Mosen-Ansorena D, *et al*. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. *Nature genetics*. 2018;50(10):1412–1425.
49. System URD. USRDS 2013 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. *National Institutes of Health, National Institute of Diabetes and Digestive and Digestive and Kidney Diseases, Vol. 2014*. 2013.
50. Coresh J, Wei GL, McQuillan G, *et al*. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). *Archives of internal medicine*. 2001;161(9):1207–1216.
51. Jacobsen P, Rossing K, Tarnow L, *et al*. Progression of diabetic nephropathy in normotensive type 1 diabetic patients. *Kidney International*. 1999;56:S101–S105.
52. Klahr S, Levey AS, Beck GJ, *et al*. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. *New England Journal of Medicine*. 1994;330(13):877–884.

53. Klag MJ, Whelton PK, Randall BL, *et al.* Blood pressure and end-stage renal disease in men. *New England Journal of Medicine*. 1996;334(1):13–18.
54. Rosario RF, Wesson DE. Primary hypertension and nephropathy. *Current opinion in nephrology and hypertension*. 2006;15(2):130–134.
55. Hadtstein C, Schaefer F. Hypertension in children with chronic kidney disease: pathophysiology and management. *Pediatric Nephrology*. 2008;23:363–371.
56. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. *Hypertension*. 2004;44(5):595–601.
57. Bidani AK, Griffin KA. Long-term renal consequences of hypertension for normal and diseased kidneys. *Current opinion in nephrology and hypertension*. 2002;11(1):73–80.
58. Wade KH, Hamilton FW, Carslake D, Sattar N, Davey Smith G, Timpson NJ. Challenges in undertaking nonlinear Mendelian randomization. *Obesity*. 2023;31(12):2887–2890.
59. Fan L, Levey AS, Gudnason V, *et al.* Comparing GFR estimating equations using cystatin C and creatinine in elderly individuals. *Journal of the American Society of Nephrology*. 2015;26(8):1982–1989.
60. Köttgen A, Albrecht E, Teumer A, *et al.* Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. *Nature genetics*. 2013;45(2):145–154.
61. Jordan DM, Choi HK, Verbanck M, *et al.* No causal effects of serum urate levels on the risk of chronic kidney disease: a Mendelian randomization study. *PLoS medicine*. 2019;16(1):e1002725.
62. Yang Q, Köttgen A, Dehghan A, *et al.* Multiple genetic loci influence serum urate levels and

- their relationship with gout and cardiovascular disease risk factors. *Circulation: Cardiovascular Genetics*. 2010;3(6):523–530.
63. Gill D, Cameron AC, Burgess S, *et al*. Urate, blood pressure, and cardiovascular disease: evidence from mendelian randomization and meta-analysis of clinical trials. *Hypertension*. 2021;77(2):383–392.
64. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which?. *Nephrology Dialysis Transplantation*. 2013;28(9):2221–2228.
65. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. *Journal of hypertension*. 2008;26(2):269–275.
66. Khosla UM, Zharikov S, Finch JL, *et al*. Hyperuricemia induces endothelial dysfunction. *Kidney international*. 2005;67(5):1739–1742.
67. Sanchez-Lozada LG, Tapia E, Santamaria J, *et al*. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. *Kidney international*. 2005;67(1):237–247.
68. Sánchez-Lozada LG, Tapia E, López-Molina R, *et al*. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. *American Journal of Physiology-Renal Physiology*. 2007;292(4):F1238–F1244.
69. Sánchez-Lozada LG, Soto V, Tapia E, *et al*. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. *American Journal of Physiology-Renal Physiology*. 2008;295(4):F1134–F1141.



70. Sturm G, Kollerits B, Neyer U, *et al.* Uric acid as a risk factor for progression of non-diabetic chronic kidney disease? The Mild to Moderate Kidney Disease (MMKD) Study. *Experimental gerontology*. 2008;43(4):347–352.
71. Madero M, Sarnak MJ, Wang X, *et al.* Uric acid and long-term outcomes in CKD. *American Journal of Kidney Diseases*. 2009;53(5):796–803.
72. Feig DI, Madero M, Jalal DI, Sanchez-Lozada LG, Johnson RJ. Uric acid and the origins of hypertension. *The Journal of pediatrics*. 2013;162(5):896–902.
73. Borghi C, Agnoletti D, Cicero AFG, Lurbe E, Virdis A. Uric acid and hypertension: a review of evidence and future perspectives for the management of cardiovascular risk. *Hypertension*. 2022;79(9):1927–1936.
74. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. *Arthritis care & research*. 2011;63(1):102–110.
75. Feig DI. The role of uric acid in the pathogenesis of hypertension in the young. *The journal of clinical hypertension*. 2012;14(6):346–352.

## Disclosure

TRG receives funding from Biogen and GSK for unrelated research.

## Data Statement

The summary-level data from CKDGen are publicly available (<http://ckdgen.imbi.uni-freiburg.de/> and OpenGWAS <https://gwas.mrcieu.ac.uk/><sup>46</sup>). The UK Biobank individual-level data can be accessed through an application (<https://www.ukbiobank.ac.uk/>).

## **Acknowledgments**

The authors thank the CKDGen consortium (<https://ckdgen.imbi.uni-freiburg.de>) for publicly sharing the summary-level data. This research has been conducted using the UK Biobank Resource under Application No. 15825. This work was supported by the UK Medical Research Council Integrative Epidemiology Unit (MC\_UU\_00011/4 and MC\_UU\_00032/03).

## **Author Contributions**

HT conducted the analyses and drafted the manuscript. VMW and TRG equally contributed to the supervision and manuscript review. All authors approved the final version for submission.

Analysis	Exposure	Outcome
Univariable MR	Urate (CKDGen)	eGFR (CKDGen2019)
		SBP (UKB)
		DBP (UKB)
		Hypertension (UKB)
		Early-onset hypertension (UKB)
		Late-onset hypertension (UKB)
	Urate (UKB)	eGFR (CKDGen2019)
		Gout
	SBP (UKB)	eGFR (CKDGen2019)
		eGFR (CKDGen2016)
		Urate (CKDGen)
		Stroke
	DBP (UKB)	eGFR (CKDGen2019)
		eGFR (CKDGen2016)
		Urate (CKDGen)
		Stroke
eGFR (CKDGen2019)	Urate (CKDGen)	
	Urate (UKB)	
	SBP (UKB)	
	DBP (UKB)	
eGFR (CKDGen2016)	SBP (UKB)	
	DBP (UKB)	
Multivariable MR	Urate (CKDGen) + SBP (UKB)	eGFR (CKDGen2019)
	Urate (CKDGen) + DBP (UKB)	
	Urate (UKB Meta) + SBP (UKB Meta)	
	Urate (UKB Meta) + DBP (UKB Meta)	

Table 1: Details of all MR analyses conducted in this study. Each trait was presented as the trait name (its corresponding source). We denote urate data from CKDGen as "Urate (CKDGen)"<sup>18</sup> and from UKB as "Urate (UKB)", and distinguish two eGFR GWAS from CKDGen as "eGFR (CKDGen2019)"<sup>19</sup> and "eGFR (CKDGen2016)".<sup>20</sup> To avoid sample overlap between Urate and eGFR, Urate UKB GWAS was used in UVMR while the split-sample method, where the UKB sample was randomly divided into two to conduct GWAS, was used in MVMR. Meta indicated that causal estimates were meta-analyzed from the causal effects of the two subsets. UVMR, univariable Mendelian Randomization; MVMR, multivariable MR; UKB, UK Biobank; SBP and DBP, systolic and diastolic blood pressure; eGFR, estimated glomerular filtration rate; CKDGen, the Chronic Kidney Disease Genetics Consortium.

Sources	Trait name	Sample size (% cases, if applicable)	Subgroup
UKB	Urate	440,466	Full sample
		220,082	Sample 1
		220,081	Sample 2
	SBP	432,099	Full sample
		205,299	Sample 1
		205,512	Sample 2
	DBP	432,253	Full sample
		205,238	Sample 1
		205,512	Sample 2
	Hypertension	462,826 (28.9%)	Full sample
Early-onset hypertension	336,080 (2.1%)	Full sample	
Late-onset hypertension	424,729 (22.5%)	Full sample	
CKDGen	Urate	288,649	Full sample
	log(eGFR) (CKDGen2019)	567,460	Full sample
	log(eGFR) (CKDGen2016)	133,814	Full sample
GUGC	Gout	69,374 (3.0%)	Full sample
MEGASTROKE	Stroke	446,696 (9.1%)	Full sample

Table 2: Details of all genome-wide association studies (GWAS) used in our study. All UKB GWAS were newly conducted; "Full sample" indicates that all participants were used; "Sample 1" and "Sample 2" indicate that the split-sample method was used (see details in Methods and materials). UKB, UK Biobank; SBP and DBP, systolic and diastolic blood pressure; CKDGen, the Chronic Kidney Disease Genetics Consortium; eGFR, estimated glomerular filtration rate; GUGC, Global Urate Genetics Consortium.




Figure 1: Forest plot of the pairwise bidirectional univariable MR results. Each trait is presented as the trait name (its corresponding source). Estimates of the causal effects of the following exposures: A) urate (CKDGen); B) SBP (UKB); C) DBP (UKB); D) eGFR (CKDGen2019), are presented as SD unit change in outcome per SD unit increase in exposure (eGFR is in the SD unit of log(eGFR)). CI, confidence interval; SBP and DBP, systolic and diastolic blood pressure; eGFR, estimated glomerular filtration rate; MR, Mendelian Randomization.




Figure 2: Forest plot of MR results of urate on each type of hypertension. Exposure and outcomes are presented as the trait name (its source name). Estimates of causal effects are presented as OR of each hypertension outcome per SD unit increase in urate (CKDGen). MR, Mendelian randomization; CI, confidence interval. OR, odds ratio.




Figure 3: Forest plot of MVMR of urate and BP on eGFR. Each trait is presented as the trait name (its corresponding source). Estimates of causal effects of the two sets of following exposures: A) urate (CKDGen) and SBP (UKB); B) urate (CKDGen) and DBP (UKB), are presented as SD unit change in log(eGFR) per SD unit increase in exposure. CI, confidence interval; SBP and DBP, systolic and diastolic blood pressure; eGFR, glomerular filtration rate estimated from serum creatinine; MVMR, multivariable MR.